In one of his first public addresses since becoming commissioner of the US Food and Drug Administration (FDA) for the second time, Robert Califf outlined some observations about the state of play in the healthcare sector, as well as some of his priorities surrounding data and evidence generation in his recently reprised role.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,